Life Sciences

Congress should ratify the proposed USMCA and in particular support its provision requiring 10 years of data protection for biologic drugs. The result will be a more competitive U.S. biopharmaceutical industry, more high-paying American jobs and more incentives to produce new cures.
Life Sciences
Check a box to narrow search for individual content items that cover numerous issues.
December 8, 2015
While many parts of the Trans-Pacific Partnership agreement will positively impact bio innovation, others will inhibit the development of the next generation of breakthrough medicines, said Stephen Ezell in testimony before the House Ways and Means Committee Democratic Members.
November 5, 2015
In comments to the White House Office of Science and Technology Policy, ITIF's Val Giddings argues there is no relationship between the degree of regulatory scrutiny a biotechnology product receives and the degree of hazard it represents.
June 22, 2015
A new paper shows that innovative treatments are adding years to cancer patients' lives.
April 16, 2015
Turkey's leaders need to create a more supportive environment for trade, investment, and innovation.
April 9, 2015
New research shows the value of medical innovation is much higher than previously estimated.
March 17, 2015
How Canada is killing innovation in its pharmaceutical industry.
March 16, 2015
Smart regulatory reform focused on sectors that compete internationally can boost U.S. economic competitiveness while maintaining, or even increasing, social benefits.
March 9, 2015
To ensure the Trans-Pacific Partnership (TPP) Agreement creates a framework in which life sciences innovation flourishes throughout the TPP region, it needs to include 12 years of data protection for novel biologic drugs.
February 26, 2015
The National Institutes of Health needs greater resources and more funding stability.
February 17, 2015
IP protection is essential to future medical innovation.

Pages